Wall Street Journal (September 14)
2016/ 09/ 16 by jd in Global News
“For Monsanto owners, selling to Bayer provides a premium of 44%.” With relatively little overlap between the companies, antitrust issues should be less likely to threaten the merger. Moreover, “the deal seems to make strategic sense, as Bayer combines its pesticides franchise with a leader in seeds and biotechnology. Bayer is also known for health care, which will generate about half of the combined company’s sales. Crop sciences will contribute roughly the other half.”
Tags: Antitrust, Bayer, Biotechnology, Crop sciences, Health care, Merger, Monsanto, Overlap, Pesticides, Premium, Seeds
